| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT07082465 Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four… |
overall status: Not Yet Recruiting → Active, Not Recruiting |
| 2026-08-15 | NCT07082465 Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four… |
date change Primary completion moved earlier: 2026-08-16 -> 2026-06-30 |
| 2026-08-15 | NCT07082465 Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four… |
date change Completion pushed: 2026-08-16 -> 2027-11-30 |
| 2026-08-11 | NCT05511285 Improving Sleep and Learning in Rehabilitation After Stroke, Part 2 |
date change Primary completion pushed: 2026-04 -> 2027-06 |
| 2026-08-11 | NCT05511285 Improving Sleep and Learning in Rehabilitation After Stroke, Part 2 |
date change Completion pushed: 2026-06 -> 2027-12 |
| 2026-08-07 | NCT07602920 Gut Leakage' in Dengue |
Recruitment opened |
| 2026-08-06 | NCT07470424 A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination… |
date change Primary completion pushed: 2027-06-01 -> 2027-11-01 |
| 2026-08-06 | NCT07470424 A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination… |
date change Completion pushed: 2027-08-01 -> 2027-11-01 |
| 2026-08-02 | NCT04838106 Outcomes of Patients Who Survived Treatment on an Intensive Care Unit for COVID-19 in… |
overall status: Active, Not Recruiting → Unknown |
| 2026-08-01 | NCT05169333 The Oxford Risk Factors And Non-Invasive Imaging Study |
Trial sites expanded: 37 -> 45 locations |
| 2026-07-30 | NCT04704999 Southeast Asia Dose Optimization of Tafenoquine |
Enrollment increased: 700 -> 820 participants |
| 2026-07-30 | NCT04704999 Southeast Asia Dose Optimization of Tafenoquine |
Trial arms changed: 2 -> 3 |
| 2026-07-24 | NCT07215195 Neuropsychiatric Outcomes and Disrupted Sleep Following Acquired Brain Injury |
Recruitment opened |
| 2026-07-24 | NCT06821282 Surveillance of AMR in DRC |
date change Primary completion pushed: 2025-03-30 -> 2026-09-30 |
| 2026-07-24 | NCT06821282 Surveillance of AMR in DRC |
date change Completion pushed: 2025-09-30 -> 2026-09-30 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06731374 | Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15 | Pneumococcal Disease | Recruiting |
| NCT06068530 | Mass Vaccine and Drug Administration, Bangladesh | Plasmodium Falciparum Malaria | Recruiting |
| NCT07267559 | Dual Orexin Antagonism and Emotion and Affective Processing Study | Learning | Recruiting |
| NCT04704999 | Southeast Asia Dose Optimization of Tafenoquine | Plasmodium Vivax Malaria | Recruiting |
| NCT00135226 | ASCEND: A Study of Cardiovascular Events iN Diabetes | Diabetes Mellitus | Active, Not Recruiting |
| NCT03083197 | Scrub Typhus Antibiotic Resistance Trial | Scrub Typhus | Active, Not Recruiting |
| NCT05441267 | A Study of Cardiovascular Events iN Diabetes Plus | Diabetes Mellitus, Type 2 | Active, Not Recruiting |
| NCT07194668 | R21/MM Dosing, Presentations, and Preservatives | Plasmodium Falciparum Malaria | Not Yet Recruiting |
| Phase 3 | |||
| NCT07093359 | LINX vs Fundoplication | Gastro-oesophageal Reflux Disease | Recruiting |
| NCT05951595 | A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as… | Uncomplicated Plasmodium Falciparum Malaria | Recruiting |
| NCT04381936 | Randomised Evaluation of COVID-19 Therapy | Pneumonia | Recruiting |
| NCT01252953 | REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification | Atherosclerotic Cardiovascular Disease | Active, Not Recruiting |
| NCT06778564 | Stratification and Treatment in Early Psychosis Study - ENHANCE | Psychosis | Not Yet Recruiting |
| NCT07326124 | Stratification and Treatment in Early Psychosis Study -ASSIST | Treatment Resistant Psychosis | Not Yet Recruiting |
| NCT04704830 | R21/Matrix-M in African Children Against Clinical Malaria | Malaria | Active, Not Recruiting |
| NCT07434973 | Stratification and Treatment in Early Psychosis Study - PROMOTE | Clinical High Risk for Psychosis (CHR) | Not Yet Recruiting |
| NCT03705234 | A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People… | Atherosclerotic Cardiovascular Disease | Active, Not Recruiting |
| Phase 2 | |||
| NCT06488300 | Assessing Antiviral Treatments in Early Symptomatic RSV | Respiratory Syncytial Virus | Recruiting |
| NCT05041907 | Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early… | COVID-19 | Recruiting |
| NCT07074665 | Dose Finding Trial of R21/Matrix-M in School Children | Malaria (Plasmodium Falciparum) | Recruiting |
| NCT05648448 | A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza | Influenza | Recruiting |
| NCT07054931 | Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV | HIV | Recruiting |
| NCT05315258 | Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma | Melanoma (Skin) | Active, Not Recruiting |
| NCT03782636 | Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD) | Type1 Diabetes | Active, Not Recruiting |
| NCT06799234 | Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003) | Rift Valley Fever | Active, Not Recruiting |